Heart Failure Therapy Comparison: Key Trial Overview
Managing symptomatic heart failure requires optimal medication strategies. Therefore, a direct heart failure therapy comparison provides valuable clinical clarity for treating clinicians. Recently, researchers evaluated health status outcomes in patients with symptomatic heart failure and reduced ejection fraction. Specifically, the randomized LAQUA-HF trial compared sacubitril-valsartan against dapagliflozin. Additionally, the study evaluated torsemide against furosemide in the same cohort.
Trial Design and Patient Outcomes
In this trial, investigators enrolled 231 ambulatory adults across tertiary centers in Japan. Furthermore, all participants had symptomatic heart failure with ejection fractions below 50 percent. Consequently, patients received either sacubitril-valsartan or dapagliflozin over six months. Similarly, clinicians randomly assigned patients to receive torsemide or furosemide. Ultimately, patient-reported health status scores showed no significant differences between the intervention groups at six months. Moreover, both treatment regimens maintained comparable safety profiles throughout the study period.
Clinical Implications for Physicians
Overall, these findings highlight flexibility when selecting guideline-directed medical therapy. However, clinicians must still tailor regimens based on individual patient tolerance and cost. In addition, both ARNI and SGLT2 inhibitor classes remain foundational pillars for heart failure management. Therefore, doctors can choose either drug class based on comorbidity profiles and patient preferences.
Frequently Asked Questions
Q1: Did sacubitril-valsartan outperform dapagliflozin in improving health status at 6 months?
No, the trial demonstrated that patient-reported health status did not differ significantly between sacubitril-valsartan and dapagliflozin at 6 months.
Q2: Was torsemide superior to furosemide for health status outcomes in this study?
However, torsemide did not show superiority over furosemide regarding patient-reported health status at 6 months.
Q3: What are the main clinical takeaways for heart failure management?
Consequently, clinicians can individualize drug choices based on cost, comorbidities, and patient tolerability without compromising short-term health status.
References
- Steinberg DI et al. In symptomatic HF, sacubitril-valsartan vs. dapagliflozin and torsemide vs. furosemide did not differ for health status at 6 mo. Ann Intern Med. 2026 Aug 04. doi: 10.7326/ANNALS-26-02647-JC. PMID: 42546309.
- Mentz RJ et al. Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial. JAMA. 2023;329(3):214-223.